NRX:CA:TSV-NurExone Biologic Inc. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.76

Change

-0.02 (-2.56)%

Market Cap

USD 0.04B

Volume

0.33M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.16B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
MIR:CA MedMira Inc

N/A

USD 0.05B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.03B
CZO:CA Ceapro

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

N/A

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing NRX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 157.63% 95% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 157.63% 95% A 98% N/A
Trailing 12 Months  
Capital Gain 117.14% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 117.14% 100% F 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.10% 54% F 45% F
Dividend Return -4.10% 54% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.08% 58% F 59% D-
Risk Adjusted Return -10.76% 50% F 45% F
Market Capitalization 0.04B 88% B+ 81% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.